Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Molecular Pathology Research Laboratory, |
RCV001542153 | SCV001760821 | likely pathogenic | Deafness-lymphedema-leukemia syndrome; GATA2 deficiency with susceptibility to MDS/AML | 2021-07-06 | criteria provided, single submitter | curation | PVS1_Strong, PS4_Supporting, PM2 |
Labcorp Genetics |
RCV003764625 | SCV004569784 | pathogenic | Deafness-lymphedema-leukemia syndrome; Monocytopenia with susceptibility to infections | 2023-10-19 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 4 of the GATA2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GATA2 are known to be pathogenic (PMID: 21670465, 23223431). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with GATA2-related conditions (PMID: 21670465, 21765025, 26022708). ClinVar contains an entry for this variant (Variation ID: 29716). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
OMIM | RCV000022568 | SCV000043857 | pathogenic | Monocytopenia with susceptibility to infections | 2011-09-08 | no assertion criteria provided | literature only |